A Phase 2 trial of AU-011 via suprachoroidal administration with a dose escalation phase (open-label, ascending single and repeat dose) and a randomized, masked dose expansion phase designed to evaluate the safety and efficacy of AU-011 in subjects with primary indeterminate lesions and small choroidal melanoma
This study is being conducted on patients diagnosed with a type of eye cancer called choroidal melanoma or an indeterminate lesion (a growth in your eye that is suspected to be melanoma), also known as eye melanoma. People who have choroidal melanoma are usually treated with radiation ther...
Protocol #: 20-1186
|
Evaluating the Effects of Cannabis Use and Circulating Cannabinoids on Tumor Infiltrating Lymphocytes in Malignant Melanoma
Protocol #: 22-1132
Location: University of Colorado Hospital
|
A phase 2 study of brentuximab vedotin in combination with pembrolizumab in subjects with metastatic solid malignancies
Protocol #: 20-2383
Location: University of Colorado Hospital
|
Paired Germline/Tumor Genetic Testing Outcomes
Protocol #: 20-2287
Location: Childrens Hospital Colorado, Childrens Hospital Colorado at Memorial
|
A PHASE 1, OPEN-LABEL, MULTI-CENTER, DOSE-FINDING, PHARMACOKINETIC, SAFETY AND TOLERABILITY STUDY OF PF-07265807 IN PARTICIPANTS WITH SELECTED ADVANCED OR METASTATIC SOLID TUMOR MALIGNANCIES
Protocol #: 20-1845
Location: University of Colorado Hospital
|
A First-in-Human, Two-Part, Open-Label, Phase I/II Study of DSP107 in Subjects with Advanced Solid Tumors Including a Dose-Escalation Safety Study (Part 1) and Preliminary Efficacy Assessment of DSP107 as Monotherapy and in Combination with Atezolizumab (Part 2)
Part 1 of the study is open to all solid tumors. Part 2 of the study will evaluate the safety, tolerability and preliminary efficacy of
DSP107, administered either as monotherapy or in combination with atezolizumab.
The study will enrol subjects with NSCLC that is wildtype for actionable...
Protocol #: 20-1690
Location: University of Colorado Hospital
|
A Phase 1/2 Open-Label Rolling-Arm Umbrella Platform Design of Investigational Agents With or Without Pembrolizumab or Pembrolizumab Alone in Participants with Melanoma (KEYMAKER-U02): Substudy 02C
Protocol #: 20-0253
Location: University of Colorado Hospital
|
A Phase 1/2 First-in-human Study of BMS-986288 Alone and in Combination with Nivolumab in Advanced Malignant Tumors
Protocol #: 19-0604
Location: University of Colorado Hospital
|
CEMIPLIMAB SURVIVORSHIP EPIDEMIOLOGY (CASE) STUDY
Protocol #: 19-0519
Location: University of Colorado Hospital
|
Evaluation of Sun Protection Education using the Reveal Imager Photo-aging and the SPA Questionnaire
Protocol #: 17-2424
Location: Department Specific Free Standing Clinic, University of Colorado Cancer Center, University of Colorado Hospital
|
A Phase 1, Open-Label, Multicenter, Dose Escalation Study of mRNA-2752, a Lipid Nanoparticle Encapsulating mRNAs Encoding Human OX40L, IL-23, and IL-36, for Intratumoral Injection Alone and in Combination with Immune Checkpoint Blockade
Protocol #: 18-1526
Location: University of Colorado Hospital
|
051/02 A Phase I/II Study of Pembrolizumab (MK-3475) in Children with Advanced Melanoma or a PD-L1 Positive Advanced, Relapsed or Refractory Solid Tumor or Lymphoma (KEYNOTE-051)
Protocol #: 16-0064
Location: Childrens Hospital Colorado
|
A Phase 1 Study of AGEN2373, an Anti-CD137 Monoclonal Antibody, as Monotherapy and in Combination with AGEN1181, an Fc-Engineered Anti-CTLA-4 Monoclonal Antibody, in Patients with Advanced Cancer
Protocol #: 22-0326
Location: CTRC Inpatient, University of Colorado Hospital
|
S2101: Biomarker Stratified CaboZantinib (NSC#761968) and NivOlumab (NSC#748726)
(BiCaZO) - A Phase II Study of Combining Cabozantinib and Nivolumab in Participants with Advanced Solid Tumors (IO Refractory Melanoma or HNSCC) Stratified by Tumor Biomarkers - an immunoMATCH Pilot Study
Protocol #: 22-2225
Location: Rocky Mountain Regional VA Medical Center
|
Phase 1/2 Study of mRNA-4359 Administered Alone and in Combination With Immune Checkpoint Blockade in Participants with Advanced Solid Tumors
Protocol #: 22-1490
Location: University of Colorado Hospital
|
A PHASE 1/2, OPEN LABEL, DOSE ESCALATION AND EXPANSION STUDY OF TAC-001 IN PATIENTS WITH SELECT ADVANCED OR METASTATIC SOLID TUMORS
Protocol #: 22-1188
Location: CTRC Inpatient, University of Colorado Hospital
|
A Phase 1/2 Study of ANV419 as Monotherapy or in Combination With Anti-PD-1 or Anti-CTLA-4 Antibody Following Anti-PD-1/Anti-PD-L1 Antibody Treatment in Patients With Unresectable or Metastatic Cutaneous Melanoma
Protocol #: 22-1121
Location: CTRC Inpatient, Outpatient CTRC, University of Colorado Hospital
|
A Phase 1, Open-Label, First in Human, Dose Escalation Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of ZX-4081 in Patients with Advanced Solid Tumors
Protocol #: 22-0318
Location: Outpatient CTRC, University of Colorado Hospital
|
A Phase 1/1b, Open-Label Study of the Pressure-Enabled Hepatic Artery Infusion of SD-101, a TLR9 Agonist, Alone or in Combination with Intravenous Checkpoint Blockade in Adults with Metastatic Uveal Melanoma
Protocol #: 21-3200
Location: CTRC Inpatient, Outpatient CTRC, University of Colorado Hospital
|
A Phase 1/2 Open-Label Rolling-Arm Umbrella Platform Design of Investigational Agents With or Without Pembrolizumab or Pembrolizumab Alone in Participants With Melanoma (KEYMAKER-U02): Substudy 02D
Protocol #: 21-3366
Location: University of Colorado Hospital
|
S2000 - A Randomized Phase 2 Trial of Encorafenib + Binimetinib + Nivolumab Vs Ipilimumab + Nivolumab in BRAF-V600 Mutant Melanoma with Brain Metastases
Protocol #: 21-2584
Location: University of Colorado Hospital
|
AN OPEN-LABEL, MULTICENTER, PHASE 1B/2 STUDY OF RP1 IN SOLID ORGAN TRANSPLANT RECIPIENTS WITH ADVANCED CUTANEOUS MALIGNANCIES
Protocol #: 19-2987
Location: University of Colorado Hospital
|
A Phase 3, Randomized, Double-blind, Placebo-controlled Study to Evaluate Pembrolizumab Versus Placebo as Adjuvant Therapy Following Surgery and Radiation in Participants with High-risk Locally Advanced Cutaneous Squamous Cell Carcinoma (LA cSCC) (KEYNOTE-630)
Protocol #: 18-2692
Location: University of Colorado Hospital
|
Phase 1b/2, Open-Label Study Evaluating the Safety and Efficacy of KRT-232 in Patients with p53 Wild-Type (p53WT) Merkel Cell Carcinoma (MCC) Who Have Failed Anti-PD-1 or Anti-PD-L1 Immunotherapy, or in Combination with Avelumab in MCC Patients who are Anti-PD-1 or Anti-PD-L1 Treatment Naive
Protocol #: 18-2284
Location: University of Colorado Hospital
|
A multicenter, randomized, double-blinded, placebo-controlled, Phase 3 trial of adjuvant Avelumab (anti-PDL-1 antibody) in Merkel cell carcinoma patients with lymph node metastases
Protocol #: 18-1734
Location: University of Colorado Hospital
|
A Phase II Study of Talimogene laherparepvec Followed by Talimogene laherparepvec + Nivolumab in Refractory T Cell and NK Cell Lymphomas, Cutaneous Squamous Cell Carcinoma, Merkel Cell Carcinoma, and Other Rare Skin Tumors
Protocol #: 18-1265
Location: University of Colorado Hospital
|
Open Label Phase 2 Study of Tisotumab Vedotin for Locally Advanced or Metastatic Disease in Solid Tumors
Protocol #: 18-6055
Location: Greeley Campus, Harmony Campus, Medical Center of the Rockies, Poudre Valley Hospital
|
A Phase 1, Open-Label, Safety and Tolerability Study of INCB057643 in Participants With Myelofibrosis and Other Advanced Myeloid Neoplasms
Protocol #: 22-0130
Location: CTRC Inpatient, University of Colorado Hospital
|
Safety, Pharmacokinetics (PK), and Efficacy of ONC-392 as a Single Agent and in Combination with Pembrolizumab in Advanced Solid Tumors and NSCLC: An Open-label Phase IA/IB Study
Protocol #: 22-0094
Location: CTRC Inpatient, University of Colorado Hospital
|
Total Cancer Care Protocol: A Lifetime Partnership with Patients Who Have or May be at Risk of Having Cancer (ORIEN)
Protocol #: 15-1110
Location: Cherry Creek Medical Center, Memorial Hospital Central, Memorial Hospital North, Poudre Valley Hospital, University of Colorado Hospital
|
A Phase II, Multicenter, Single-Arm Clinical Trial of Definitive Radiotherapy And CeMiPlimAb-Rwlc ImmunoTherapy for Locally Advanced, Unresectable Cutaneous Squamous Cell Carcinoma: RAMPART
Protocol #: 22-1922
Location: Highlands Ranch Hospital, University of Colorado Hospital
|
